TMEM30CP
Cell cycle control protein 50C
Also known as: CC50C_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for TMEM30CP in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
113 residues, UniProt reviewed canonical sequence.
>A0ZSE6|TMEM30CP
1 MEERAQHCLS RLLDNSALKQ QELPIHRLYF TARRVLFVFF ATGIFCLCMG IILILSARST
61 QEIEINYTRI CANCAKLREN ASNFDKECTC SIPFYLSGKM MVGEIQETRL TLHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TMEM30CP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.57
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TMEM30CP as an antibody target. Whether an autoantibody or antibody against TMEM30CP could matter depends on whether native TMEM30CP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TMEM30CP is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TMEM30CP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...